[go: up one dir, main page]

IL244237A0 - Bi-specific monovalent diabodies that are capable of binding cd123 and cd3, and uses therof - Google Patents

Bi-specific monovalent diabodies that are capable of binding cd123 and cd3, and uses therof

Info

Publication number
IL244237A0
IL244237A0 IL244237A IL24423716A IL244237A0 IL 244237 A0 IL244237 A0 IL 244237A0 IL 244237 A IL244237 A IL 244237A IL 24423716 A IL24423716 A IL 24423716A IL 244237 A0 IL244237 A0 IL 244237A0
Authority
IL
Israel
Prior art keywords
binding
specific monovalent
monovalent diabodies
uses therof
therof
Prior art date
Application number
IL244237A
Other languages
Hebrew (he)
Other versions
IL244237B (en
Original Assignee
Macrogenics Inc
Leslie s johnson
Ling Huang
Ezio Bonvini
Paul A Moore
Gurunadh Reddy Chichili
Ralph Froman Alderson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Macrogenics Inc, Leslie s johnson, Ling Huang, Ezio Bonvini, Paul A Moore, Gurunadh Reddy Chichili, Ralph Froman Alderson filed Critical Macrogenics Inc
Publication of IL244237A0 publication Critical patent/IL244237A0/en
Publication of IL244237B publication Critical patent/IL244237B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Materials For Photolithography (AREA)
  • Detergent Compositions (AREA)
  • Compounds Of Alkaline-Earth Elements, Aluminum Or Rare-Earth Metals (AREA)
  • Polyesters Or Polycarbonates (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Removal Of Specific Substances (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL244237A 2013-08-23 2016-02-22 Bi-specific monovalent diabodies that are capable of binding cd123 and cd3, and uses therof IL244237B (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361869510P 2013-08-23 2013-08-23
US201361907749P 2013-11-22 2013-11-22
EP13198784.4A EP2839842A1 (en) 2013-08-23 2013-12-20 Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof
US201461990475P 2014-05-08 2014-05-08
PCT/US2014/051790 WO2015026892A1 (en) 2013-08-23 2014-08-20 Bi-specific monovalent diabodies that are capable of binding cd123 and cd3, and uses therof

Publications (2)

Publication Number Publication Date
IL244237A0 true IL244237A0 (en) 2016-04-21
IL244237B IL244237B (en) 2020-05-31

Family

ID=49882875

Family Applications (1)

Application Number Title Priority Date Filing Date
IL244237A IL244237B (en) 2013-08-23 2016-02-22 Bi-specific monovalent diabodies that are capable of binding cd123 and cd3, and uses therof

Country Status (29)

Country Link
US (3) US9822181B2 (en)
EP (3) EP2839842A1 (en)
JP (1) JP6524087B2 (en)
KR (1) KR102287523B1 (en)
CN (1) CN105873607B (en)
AP (1) AP2016009029A0 (en)
AR (1) AR097405A1 (en)
AU (1) AU2014308905B2 (en)
BR (1) BR112016003417A2 (en)
CA (1) CA2920116A1 (en)
CR (1) CR20160108A (en)
CY (1) CY1123940T1 (en)
EA (1) EA034142B1 (en)
GE (1) GEAP201914100A (en)
IL (1) IL244237B (en)
MX (1) MX373374B (en)
PE (1) PE20160509A1 (en)
PH (1) PH12016500311B1 (en)
PL (1) PL3035965T4 (en)
PT (1) PT3035965T (en)
RS (1) RS61522B1 (en)
SA (1) SA516370567B1 (en)
SG (1) SG11201601317UA (en)
SI (1) SI3035965T1 (en)
SM (1) SMT202100123T1 (en)
TN (1) TN2016000046A1 (en)
TW (1) TWI669310B (en)
WO (1) WO2015026892A1 (en)
ZA (1) ZA201600653B (en)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9963510B2 (en) 2005-04-15 2018-05-08 Macrogenics, Inc. Covalent diabodies and uses thereof
US12466897B2 (en) 2011-10-10 2025-11-11 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
US10851178B2 (en) 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
US10131710B2 (en) 2013-01-14 2018-11-20 Xencor, Inc. Optimized antibody variable regions
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
US9701759B2 (en) 2013-01-14 2017-07-11 Xencor, Inc. Heterodimeric proteins
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
AU2014205086B2 (en) 2013-01-14 2019-04-18 Xencor, Inc. Novel heterodimeric proteins
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
WO2014145907A1 (en) 2013-03-15 2014-09-18 Xencor, Inc. Targeting t cells with heterodimeric proteins
US10106624B2 (en) 2013-03-15 2018-10-23 Xencor, Inc. Heterodimeric proteins
US10519242B2 (en) 2013-03-15 2019-12-31 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
UA116479C2 (en) * 2013-08-09 2018-03-26 Макродженікс, Інк. SPECIFIC MONOVALENT Fc-DIATELY CONNECTING BACKGROUND OF THE CD32B AND CD79b AND ITS APPLICATION
US11384149B2 (en) 2013-08-09 2022-07-12 Macrogenics, Inc. Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof
JP6775422B2 (en) 2014-03-28 2020-10-28 ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． Bispecific antibody that binds to CD38 and CD3
AP2016009586A0 (en) * 2014-05-29 2016-11-30 Macrogenics Inc Tri-specific binding molecules and methods of use thereof
MX386297B (en) 2014-09-29 2025-03-18 Univ Duke Bispecific molecules comprising an hiv-1 envelope targeting arm
BR112017004810A2 (en) * 2014-11-05 2017-12-12 Hoffmann La Roche immunoassay
AU2015353409B2 (en) 2014-11-26 2019-05-09 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
US10526417B2 (en) 2014-11-26 2020-01-07 Xencor, Inc. Heterodimeric antibodies that bind CD3 and CD38
EP3237449A2 (en) 2014-12-22 2017-11-01 Xencor, Inc. Trispecific antibodies
EP3812398A3 (en) 2015-01-23 2021-07-21 Sanofi Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123
US10227411B2 (en) 2015-03-05 2019-03-12 Xencor, Inc. Modulation of T cells with bispecific antibodies and FC fusions
WO2016149710A2 (en) 2015-03-19 2016-09-22 Duke University Hiv-1 neutralizing antibodies and uses thereof
US10344077B2 (en) 2015-03-19 2019-07-09 Duke University HIV-1 neutralizing antibodies and uses thereof (V3 antibodies)
AU2016232693B2 (en) 2015-03-19 2021-08-12 Duke University HIV-1 neutralizing antibodies and uses thereof
WO2016149695A1 (en) 2015-03-19 2016-09-22 Duke University HIV-1 NEUTRALIZING ANTIBODIES AND USES THEREOF (CD4bs ANTIBODIES)
US10100118B2 (en) * 2015-04-08 2018-10-16 Sorrento Therapeutics, Inc. Antibody therapeutics that bind CD123
PH12017502019B1 (en) * 2015-05-08 2023-09-20 Xencor Inc Heterodimeric antibodies that bind cd3 and tumor antigens
RS66859B1 (en) * 2015-05-13 2025-06-30 Ablynx Nv T cell recruiting polypeptides based on tcr alpha/beta reactivity
CA2988768A1 (en) * 2015-06-09 2016-12-15 Memorial Sloan Kettering Cancer Center T cell receptor-like antibody agents specific for ebv latent membrane protein 2a peptide presented by human hla
TW201709932A (en) 2015-06-12 2017-03-16 西雅圖遺傳學公司 CD123 antibody and its conjugate
DK3313884T3 (en) * 2015-06-29 2021-02-22 Immunogen Inc ANTI-CD123 ANTIBODIES AND CONJUGATES AND THEIR DERIVATIVES
GEAP202215554A (en) * 2015-07-30 2022-06-10 Macrogenics Inc Pd-1-binding molecules and methods of use thereof
CN107921130A (en) * 2015-08-17 2018-04-17 宏观基因有限公司 Bispecific monovalent diabodies capable of binding B7‑H3 and CD3 and uses thereof
US10227410B2 (en) 2015-12-07 2019-03-12 Xencor, Inc. Heterodimeric antibodies that bind CD3 and PSMA
MX2018007089A (en) 2015-12-14 2019-01-30 Macrogenics Inc Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof.
US20210198368A1 (en) 2016-01-21 2021-07-01 Novartis Ag Multispecific molecules targeting cll-1
US20190017125A1 (en) * 2016-02-09 2019-01-17 Japanese Foundation For Cancer Research Diagnosis marker for rare hematopoietic tumor, test method, therapeutic agent, and screening method
US20170349660A1 (en) * 2016-06-01 2017-12-07 Xencor. Inc. Bispecific antibodies that bind cd123 and cd3
CN109310762A (en) 2016-06-07 2019-02-05 宏观基因有限公司 Conjoint therapy
CN110352070B (en) 2016-06-14 2024-09-17 Xencor股份有限公司 Bispecific checkpoint inhibitor antibodies
US11001636B2 (en) * 2016-06-15 2021-05-11 Bayer Pharma Aktiengesellschaft Specific antibody-drug-conjugates (ADCs) with KSP inhibitors and anti-CD123-antibodies
EP4050032A1 (en) 2016-06-28 2022-08-31 Xencor, Inc. Heterodimeric antibodies that bind somatostatin receptor 2
TWI790206B (en) * 2016-07-18 2023-01-21 法商賽諾菲公司 Bispecific antibody-like binding proteins specifically binding to cd3 and cd123
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
PH12019500609B1 (en) * 2016-09-21 2024-02-21 Aptevo Res & Development Llc Cd123 binding proteins and related compositions and methods
CR20230179A (en) 2016-10-14 2023-06-12 Xencor Inc IL15/IL15Ra HETERODIMERIC FC-FUSION PROTEINS
JP7222888B2 (en) 2016-11-16 2023-02-15 アブリンクス エン．ヴェー． T cell engaging polypeptides capable of binding CD123 and TCR alpha/beta
CN110352068A (en) 2016-12-02 2019-10-18 南加利福尼亚大学 The immunity receptor and its application method of synthesis
CN118126180A (en) 2016-12-22 2024-06-04 第一三共株式会社 Anti-CD3 antibodies and molecules comprising the same
MX2019009967A (en) 2017-02-24 2019-12-02 Macrogenics Inc Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof.
CN108728464A (en) * 2017-04-14 2018-11-02 深圳新诺微环生物科技有限公司 A kind of minicircle dna carrier and its preparation method and application of expression AntiHIV1 RT activity bispecific antibody
EP3628070B1 (en) * 2017-04-28 2021-09-08 Five Prime Therapeutics, Inc. Cd80 extracellular domain polypeptides for use in increasing central memory t cells
CN111132733A (en) 2017-06-30 2020-05-08 Xencor股份有限公司 Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15R α and an antigen binding domain
US11077199B2 (en) 2017-08-09 2021-08-03 Massachusetts Institute Of Technology Albumin binding peptide conjugates and methods thereof
WO2019050521A1 (en) * 2017-09-07 2019-03-14 Macrogenics, Inc. Dosing regimens of bi-specific cd123 x cd3 diabodies in the treatment of hematologic malignancies
KR101973060B1 (en) * 2017-10-20 2019-04-26 주식회사 녹십자 Antibody against cd3 and pharmaceutical composition for treating cancer comprising the same
US10981992B2 (en) 2017-11-08 2021-04-20 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
EP3706793A1 (en) 2017-11-08 2020-09-16 Xencor, Inc. Bispecific and monospecific antibodies using novel anti-pd-1 sequences
RU2020122822A (en) 2017-12-12 2022-01-13 Макродженикс, Инк. BISPECIFIC CD16 BINDING MOLECULES AND THEIR USE IN THE TREATMENT OF DISEASES
CN111655718B (en) 2017-12-19 2025-07-22 Xencor股份有限公司 Engineered IL-2 FC fusion proteins
EP3752196A4 (en) * 2018-02-15 2022-03-23 MacroGenics, Inc. VARIANT DOMAINS OF CD3 BINDING AND THEIR USE IN MULTITHERAPIES FOR THE TREATMENT OF A DISEASE
US10982006B2 (en) 2018-04-04 2021-04-20 Xencor, Inc. Heterodimeric antibodies that bind fibroblast activation protein
US11505595B2 (en) 2018-04-18 2022-11-22 Xencor, Inc. TIM-3 targeted heterodimeric fusion proteins containing IL-15/IL-15RA Fc-fusion proteins and TIM-3 antigen binding domains
JP2021521784A (en) 2018-04-18 2021-08-30 ゼンコア インコーポレイテッド PD-1 targeted heterodimer fusion proteins containing IL-15 / IL-15RaFc fusion proteins and PD-1 antigen binding domains and their use
US20210230281A1 (en) * 2018-04-27 2021-07-29 Novartis Ag Dosing of a bispecific antibody that bind cd123 and cd3
EP3801617A1 (en) * 2018-06-01 2021-04-14 Novartis Ag Dosing of a bispecific antibody that bind cd123 and cd3
CN110606891B (en) * 2018-06-17 2022-12-06 上海健信生物医药科技有限公司 Antibody molecule aiming at human CLDN18.2, antigen binding fragment and medical application thereof
SG11202103192RA (en) 2018-10-03 2021-04-29 Xencor Inc Il-12 heterodimeric fc-fusion proteins
MX2021004868A (en) * 2018-10-30 2021-09-08 Macrogenics Inc Bispecific cd123 x cd3 diabodies for the treatment of hematologic malignancies.
AU2020232605A1 (en) 2019-03-01 2021-10-21 Xencor, Inc. Heterodimeric antibodies that bind ENPP3 and CD3
CN111349163B (en) 2020-02-05 2024-07-16 北京智仁美博生物科技有限公司 Monoclonal antibodies against CD123
KR20220144821A (en) 2020-02-21 2022-10-27 마크로제닉스, 인크. CD137 binding molecules and uses thereof
WO2021231976A1 (en) 2020-05-14 2021-11-18 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
JP2023527164A (en) * 2020-05-19 2023-06-27 ヤンセン バイオテツク，インコーポレーテツド Compositions comprising T-cell redirecting therapeutics and VLA-4 adhesion pathway inhibitors
IL300666A (en) 2020-08-19 2023-04-01 Xencor Inc Anti-cd28 compositions
HRP20250696T1 (en) 2021-01-28 2025-08-01 Regeneron Pharmaceuticals, Inc. COMPOSITIONS AND METHODS FOR TREATING CYTOKINE RELEASE SYNDROME
JP2024511319A (en) 2021-03-09 2024-03-13 ゼンコア インコーポレイテッド Heterodimeric antibody that binds to CD3 and CLDN6
EP4304729A1 (en) 2021-03-09 2024-01-17 Molecular Partners AG Novel darpin based cd123 engagers
US11834504B2 (en) 2021-03-09 2023-12-05 Molecular Partners Ag DARPin based multi-specific t-cell engagers
JP2024509274A (en) 2021-03-10 2024-02-29 ゼンコア インコーポレイテッド Heterodimeric antibody that binds to CD3 and GPC3
IL316002A (en) 2022-04-11 2024-11-01 Regeneron Pharma Universal tumor cell killing compositions and methods
KR20250151441A (en) 2023-02-17 2025-10-21 리제너론 파마슈티칼스 인코포레이티드 Induced NK cells reactive to CD3/TAA bispecific antibodies

Family Cites Families (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US320A (en) 1837-07-31 John dainty
US5985A (en) 1848-12-26 Pianoforte-action
ATE37983T1 (en) 1982-04-22 1988-11-15 Ici Plc DELAYED RELEASE AGENT.
US4752601A (en) 1983-08-12 1988-06-21 Immunetech Pharmaceuticals Method of blocking immune complex binding to immunoglobulin FC receptors
US5128326A (en) 1984-12-06 1992-07-07 Biomatrix, Inc. Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US5985599A (en) 1986-05-29 1999-11-16 The Austin Research Institute FC receptor for immunoglobulin
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US4880078A (en) 1987-06-29 1989-11-14 Honda Giken Kogyo Kabushiki Kaisha Exhaust muffler
WO1989007142A1 (en) 1988-02-05 1989-08-10 Morrison Sherie L Domain-modified constant region antibodies
US5169933A (en) 1988-08-15 1992-12-08 Neorx Corporation Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
US5576184A (en) 1988-09-06 1996-11-19 Xoma Corporation Production of chimeric mouse-human antibodies with specificity to human tumor antigens
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
GB8916400D0 (en) 1989-07-18 1989-09-06 Dynal As Modified igg3
AU6430190A (en) 1989-10-10 1991-05-16 Pitman-Moore, Inc. Sustained release composition for macromolecular proteins
AU642932B2 (en) 1989-11-06 1993-11-04 Alkermes Controlled Therapeutics, Inc. Protein microspheres and methods of using them
US5364930A (en) 1990-10-16 1994-11-15 Northwestern University Synthetic C1q peptide fragments
GB9105245D0 (en) 1991-03-12 1991-04-24 Lynxvale Ltd Binding molecules
ES2181673T3 (en) 1991-05-01 2003-03-01 Jackson H M Found Military Med PROCESS OF TREATMENT OF INFECTIOUS RESPIRATORY DISEASES.
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
US5223408A (en) 1991-07-11 1993-06-29 Genentech, Inc. Method for making variant secreted proteins with altered properties
AU2605592A (en) 1991-10-15 1993-04-22 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
US5912015A (en) 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
EP0640094A1 (en) 1992-04-24 1995-03-01 The Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
GB9225453D0 (en) 1992-12-04 1993-01-27 Medical Res Council Binding proteins
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
WO1994018330A1 (en) 1993-02-10 1994-08-18 Unilever N.V. Immobilized proteins with specific binding capacities and their use in processes and products
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
DE69434520T3 (en) 1993-07-30 2009-10-15 Affymax, Inc., Palo Alto BIOTINYLATION OF PROTEINS
GB9316989D0 (en) 1993-08-16 1993-09-29 Lynxvale Ltd Binding molecules
DE69522216T2 (en) 1994-05-13 2002-05-02 Biovation Ltd Target cell-binding chimeric peptides
ATE252894T1 (en) 1995-01-05 2003-11-15 Univ Michigan SURFACE-MODIFIED NANOPARTICLES AND METHODS FOR THEIR PRODUCTION AND USE
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
EP0850051A2 (en) 1995-08-31 1998-07-01 Alkermes Controlled Therapeutics, Inc. Composition for sustained release of an agent
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
US6750334B1 (en) 1996-02-02 2004-06-15 Repligen Corporation CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
US5942328A (en) 1996-02-29 1999-08-24 International Business Machines Corporation Low dielectric constant amorphous fluorinated carbon and method of preparation
PT885002E (en) 1996-03-04 2011-07-14 Massachusetts Inst Technology Materials and methods for enhancing cellular internalization
AU728657B2 (en) 1996-03-18 2001-01-18 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US6699658B1 (en) 1996-05-31 2004-03-02 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US6300065B1 (en) 1996-05-31 2001-10-09 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
CA2262405A1 (en) 1996-08-02 1998-02-12 Bristol-Myers Squibb Company A method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis
US6025485A (en) 1997-02-14 2000-02-15 Arcaris, Inc. Methods and compositions for peptide libraries displayed on light-emitting scaffolds
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
PT954282E (en) 1997-01-16 2005-06-30 Massachusetts Inst Technology PREPARATION OF PARTICLES FOR INHALATION
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
DE19721700C1 (en) 1997-05-23 1998-11-19 Deutsches Krebsforsch Mutant OKT3 antibody
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
SE512663C2 (en) 1997-10-23 2000-04-17 Biogram Ab Active substance encapsulation process in a biodegradable polymer
EP1060194A1 (en) 1998-02-25 2000-12-20 Lexigen Pharmaceuticals Corp. Enhancing the circulating half-life of antibody-based fusion proteins
US6455263B2 (en) 1998-03-24 2002-09-24 Rigel Pharmaceuticals, Inc. Small molecule library screening using FACS
DK1068241T3 (en) 1998-04-02 2008-02-04 Genentech Inc Antibody variants and fragments thereof
US6242195B1 (en) 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
SE9802213D0 (en) 1998-06-18 1998-06-18 Amersham Pharm Biotech Ab A method for the removal / purification of serum albumins and means for use in the method
EP1089712B1 (en) 1998-06-24 2003-05-02 Advanced Inhalation Research, Inc. Large porous particles emitted from an inhaler
WO2000009560A2 (en) 1998-08-17 2000-02-24 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
US7315786B2 (en) 1998-10-16 2008-01-01 Xencor Protein design automation for protein libraries
MX353234B (en) 1999-01-15 2018-01-08 Genentech Inc Polypeptide variants with altered effector function.
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7527787B2 (en) 2005-10-19 2009-05-05 Ibc Pharmaceuticals, Inc. Multivalent immunoglobulin-based bioactive assemblies
DE19937264A1 (en) 1999-08-06 2001-02-15 Deutsches Krebsforsch F¶v¶ antibody constructs
US20040038339A1 (en) 2000-03-24 2004-02-26 Peter Kufer Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex
CA2410551A1 (en) 2000-06-30 2002-01-10 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw (Vib) Heterodimeric fusion proteins
DE60143544D1 (en) 2000-12-12 2011-01-05 Medimmune Llc MOLECULES WITH LONGER MID-TERM, COMPOSITIONS AND THEIR USE
JP4229704B2 (en) 2001-04-18 2009-02-25 ダイアックス、コープ Fc region polypeptide binding molecule
MXPA04003291A (en) 2001-10-12 2004-07-23 Schering Corp Use of bispecific antibodies to regulate immune responses.
WO2003033666A2 (en) 2001-10-16 2003-04-24 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Broadly cross-reactive neutralizing antibodies against human immunodeficiency virus selected by env-cd4-co-receptor complexes
US20050142539A1 (en) 2002-01-14 2005-06-30 William Herman Targeted ligands
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US20040110226A1 (en) 2002-03-01 2004-06-10 Xencor Antibody optimization
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
EP1354600A1 (en) 2002-04-19 2003-10-22 Affimed Therapeutics AG Antibody combination useful for tumor therapy
JP2006506954A (en) 2002-04-29 2006-03-02 ゲンパト７７ ファーマコジェネティクス エージー Novel antibodies that bind to TCR and TIRC7 and their use in therapy and diagnosis
AU2003232456B2 (en) 2002-05-30 2009-06-04 Macrogenics, Inc. CD16A binding proteins and use for the treatment of immune disorders
AU2003245664A1 (en) 2002-06-21 2004-01-06 Dyax Corporation Serum protein-associated target-specific ligands and identification method therefor
US8193318B2 (en) 2002-08-14 2012-06-05 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
DK1534335T4 (en) 2002-08-14 2015-10-05 Macrogenics Inc FCGAMMARIIB-SPECIFIC ANTIBODIES AND PROCEDURES FOR USE THEREOF
US8187593B2 (en) 2002-08-14 2012-05-29 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8044180B2 (en) 2002-08-14 2011-10-25 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
ATE541857T1 (en) 2002-09-27 2012-02-15 Xencor Inc OPTIMIZED FC VARIANTS AND MANUFACTURING PROCESSES THEREOF
US7355008B2 (en) 2003-01-09 2008-04-08 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
US7960512B2 (en) 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
EP1596804A4 (en) 2003-01-13 2008-02-06 Macrogenics Inc SOLUBLE FcyR FUSION PROTEINS AND METHODS OF USE THEREOF
DE10303664A1 (en) 2003-01-23 2004-08-12 Nemod Immuntherapie Ag Detection molecules for the treatment and detection of tumors
AU2004255216B2 (en) 2003-07-01 2010-08-19 Immunomedics, Inc. Multivalent carriers of bi-specific antibodies
WO2005070963A1 (en) 2004-01-12 2005-08-04 Applied Molecular Evolution, Inc Fc region variants
CA2563379A1 (en) 2004-03-31 2005-10-20 Centocor, Inc. Human glp-1 mimetibodies, compositions, methods and uses
US8642743B2 (en) 2004-04-06 2014-02-04 Affibody Ab Method for reducing the immune response to a biologically active protein
CA2563314A1 (en) 2004-04-16 2005-12-08 Macrogenics, Inc. Fcyriib-specific antibodies and methods of use thereof
JP2007536932A (en) 2004-05-10 2007-12-20 マクロジェニクス，インコーポレーテッド Humanized FcγRIIB specific antibody and method of use thereof
US7432419B2 (en) 2004-05-14 2008-10-07 Los Alamos National Security, Llc Compositions and methods for the treatment of Pierce's disease
JP2008503217A (en) 2004-06-18 2008-02-07 アンブレツクス・インコーポレイテツド Novel antigen-binding polypeptides and their use
PL2213683T3 (en) 2004-08-04 2013-10-31 Mentrik Biotech Llc Variant Fc regions
EP1810035A4 (en) 2004-11-10 2010-03-17 Macrogenics Inc EFFECTOR FUNCTION OBTAINED BY CREATION BY BIOLOGICAL GENE OF FC ANTIBODY REGIONS
US20060193849A1 (en) 2005-02-25 2006-08-31 Antisoma Plc Biological materials and uses thereof
US9284375B2 (en) 2005-04-15 2016-03-15 Macrogenics, Inc. Covalent diabodies and uses thereof
ES2707152T3 (en) 2005-04-15 2019-04-02 Macrogenics Inc Covalent diabodies and uses thereof
PL1919503T3 (en) 2005-08-10 2015-04-30 Macrogenics Inc Identification and engineering of antibodies with variant fc regions and methods of using same
EP1820513A1 (en) * 2006-02-15 2007-08-22 Trion Pharma Gmbh Destruction of tumor cells expressing low to medium levels of tumor associated target antigens by trifunctional bispecific antibodies
EP2021029B1 (en) 2006-05-26 2014-06-11 MacroGenics, Inc. Humanized fc gamma riib-specific antibodies and methods of use thereof
US8163279B2 (en) * 2007-04-13 2012-04-24 Stemline Therapeutics, Inc. IL3Rα antibody conjugates and uses thereof
PL2158221T3 (en) 2007-06-21 2019-02-28 Macrogenics, Inc. Covalent diabodies and uses thereof
EP2014680A1 (en) 2007-07-10 2009-01-14 Friedrich-Alexander-Universität Erlangen-Nürnberg Recombinant, single-chain, trivalent tri-specific or bi-specific antibody derivatives
EP3375790A1 (en) * 2008-10-01 2018-09-19 Amgen Research (Munich) GmbH Cross-species-specific single domain bispecific single chain antibody
AU2009335798B2 (en) 2008-12-19 2014-11-27 Macrogenics, Inc. Covalent diabodies and uses thereof
EP2975051B1 (en) 2009-06-26 2021-04-14 Regeneron Pharmaceuticals, Inc. Readily isolated bispecific antibodies with native immunoglobulin format
AU2010303415B2 (en) 2009-10-07 2015-02-19 Macrogenics, Inc. Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use
JP6018507B2 (en) * 2010-02-17 2016-11-02 シーエスエル、リミテッド Compositions and methods for targeting type I interferon producing cells - Patents.com
ES2667100T3 (en) 2010-08-02 2018-05-09 Macrogenics, Inc. Covalent Diabodies and Their Uses
NZ604510A (en) 2010-08-17 2013-10-25 Csl Ltd Dilutable biocidal compositions and methods of use
JP6145088B2 (en) 2011-05-21 2017-06-07 マクロジェニクス，インコーポレーテッド Deimmunized serum binding domain and its use to extend serum half-life
MY173899A (en) 2011-05-21 2020-02-26 Macrogenics Inc Cd3-binding molecules capable of binding to human and non-human cd3
US9718893B2 (en) 2011-12-19 2017-08-01 Synimmune Gmbh Bispecific antibody molecule
US20130280220A1 (en) * 2012-04-20 2013-10-24 Nabil Ahmed Chimeric antigen receptor for bispecific activation and targeting of t lymphocytes
SMT202200295T1 (en) * 2012-05-18 2022-09-14 Aptevo Res & Development Llc Bispecific scfv immunofusion (bif) binding to cd123 and cd3

Also Published As

Publication number Publication date
CN105873607B (en) 2020-01-14
US9822181B2 (en) 2017-11-21
GEAP201914100A (en) 2019-08-26
KR20160045134A (en) 2016-04-26
PH12016500311A1 (en) 2016-05-16
EP3808776A1 (en) 2021-04-21
IL244237B (en) 2020-05-31
AR097405A1 (en) 2016-03-09
SMT202100123T1 (en) 2021-05-07
AU2014308905B2 (en) 2019-05-16
SG11201601317UA (en) 2016-03-30
AU2014308905A1 (en) 2016-03-10
PL3035965T3 (en) 2021-05-17
RS61522B1 (en) 2021-03-31
EA201690443A1 (en) 2016-08-31
PL3035965T4 (en) 2021-08-16
JP2017504577A (en) 2017-02-09
MX2016002260A (en) 2016-06-06
KR102287523B1 (en) 2021-08-09
SI3035965T1 (en) 2021-07-30
PH12016500311B1 (en) 2022-02-11
PE20160509A1 (en) 2016-05-21
TW201542593A (en) 2015-11-16
CR20160108A (en) 2016-07-13
WO2015026892A1 (en) 2015-02-26
EP3035965A1 (en) 2016-06-29
CN105873607A (en) 2016-08-17
MX373374B (en) 2020-05-12
TN2016000046A1 (en) 2017-07-05
TWI669310B (en) 2019-08-21
AP2016009029A0 (en) 2016-02-29
US20160200827A1 (en) 2016-07-14
CY1123940T1 (en) 2022-05-27
EA034142B1 (en) 2020-01-09
EP2839842A1 (en) 2015-02-25
SA516370567B1 (en) 2021-09-15
BR112016003417A2 (en) 2017-12-05
US10787521B2 (en) 2020-09-29
EP3035965B1 (en) 2020-11-11
ZA201600653B (en) 2017-07-26
JP6524087B2 (en) 2019-06-05
EP3035965A4 (en) 2017-03-01
US20210047426A1 (en) 2021-02-18
CA2920116A1 (en) 2015-02-26
PT3035965T (en) 2021-03-18
US20180094072A1 (en) 2018-04-05

Similar Documents

Publication Publication Date Title
IL244237A0 (en) Bi-specific monovalent diabodies that are capable of binding cd123 and cd3, and uses therof
IL251377A0 (en) Bi-specific monovalent diabodies that are capable of binding cd19 and cd3, and uses thereof
IL244238B (en) Bi-specific monovalent diabodies that are capable of binding to gpa33 and cd3, and uses thereof
IL257562A (en) Bispecific monovalent diabodies that are capable of binding b7-h3 and cd3, and uses thereof
IL244009B (en) Bi-specific monovalent fc diabodies that are capable of binding cd32b and cd79b and uses thereof
ZA201701341B (en) Bispecific her2 and cd3 binding molecules
IL248007A0 (en) Bispecific antibodies that bind to cd38 and cd3
IL247590A0 (en) Bi-specific antibodies and uses thereof
LT3035965T (en) Bi-specific monovalent diabodies that are capable of binding cd123 and cd3, and uses therof
TH1601000783A (en) Bi-specific monovalent diabodies capable of binding CD123 and CD3, and their uses

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed